Exane Derivatives’s SunOpta STKL Stock Holding History

Exane Derivatives’s Portfolio STKL Stock Details STKL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,102	Closed	-$170K	–	1074
2021 Q2	$170K	Buy	+15,102	New	+$197K	0.04%	439

Other funds holding STKL

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Exane Derivatives's STKL Position: Q3 2021 in Review

Exane Derivatives sold out of SunOpta (STKL) in Q3 2021, closing a stake of 15,102 shares — an estimated $170K sold.

Exane Derivatives first reported a position in STKL in Q2 2021 and held it in 1 quarter. The position peaked at $170K in Q2 2021. 143 funds tracked by Wall St. Rank hold STKL as of Q3 2021.

Exane Derivatives reported no remaining SunOpta position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 15,102 SunOpta shares in Q3 2021, an estimated $170K.
Exane Derivatives first reported a position in SunOpta in Q2 2021 and held it in 1 quarter.
Exane Derivatives's SunOpta position peaked at $170K in Q2 2021.
143 funds tracked by Wall St. Rank held SunOpta as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.